We are live on ! Find out more
LBPH

Longboard Pharmaceuticals, Inc. Common Stock

Delisted

LBPH was delisted on the 29th of November, 2024.

52 hedge funds and large institutions have $99.7M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 10

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

14% more capital invested

Capital invested by funds: $87.1M → $99.7M (+$12.6M)

2% more funds holding

Funds holding: 5152 (+1)

Holders
52
Holders Change
+1
Holders Change %
+1.96%
% of All Funds
0.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
23
Reduced
10
Closed
6
Calls
Puts
Net Calls
Net Calls Change

LBPH Hedge Fund Activity: Q4 2023 in Review

52 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q4 2023, worth a combined $99.7M — up 14% from $87.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LBPH positions and 6 closed out — a net gain of 1 holder — while 23 added to existing stakes and 10 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $2.4M. The largest seller was Fidelity Investments, cutting an estimated $2.31M.

  • 52 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q4 2023, up from 51 in Q3 2023.
  • Funds reported $99.7M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q4 2023, up 14% quarter-over-quarter.
  • 7 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q4 2023 and 6 closed out, a net change of +1 holder.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Jennison Associates, an estimated $2.4M added.
  • The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2023.